Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc

3
NAS:IONS (USA)  
$ 45.36 +1.38 (+3.14%) 08:08 PM EST
At Loss
P/B:
16.93
Volume:
1.70M
Avg Vol (2M):
1.24M
Also Trade In:
Volume:
1.70M
At Loss
Avg Vol (2M):
1.24M

Business Description

Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Name Current Vs Industry Vs History
Cash-To-Debt 1.6
Equity-to-Asset 0.13
Debt-to-Equity 3.76
Debt-to-EBITDA -6.16
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.49
Distress
Grey
Safe
Beneish M-Score -0.66
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 21.18
9-Day RSI 24.65
14-Day RSI 29.56
6-1 Month Momentum % 30.44
12-1 Month Momentum % 41.21

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.9
Quick Ratio 5.83
Cash Ratio 5.2
Days Inventory 989.77
Days Payable 672.07

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.9
Shareholder Yield % -3.57

Financials (Next Earnings Date:2024-05-03 Est.)

IONS's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:IONS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Ionis Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 787.647
EPS (TTM) ($) -2.56
Beta 0.07
Volatility % 25.52
14-Day RSI 29.56
14-Day ATR ($) 1.686087
20-Day SMA ($) 48.908
12-1 Month Momentum % 41.21
52-Week Range ($) 32.69 - 54.4446
Shares Outstanding (Mil) 145.75

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ionis Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Ionis Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Ionis Pharmaceuticals Inc Frequently Asked Questions

What is Ionis Pharmaceuticals Inc(IONS)'s stock price today?
The current price of IONS is $45.36. The 52 week high of IONS is $54.44 and 52 week low is $32.69.
When is next earnings date of Ionis Pharmaceuticals Inc(IONS)?
The next earnings date of Ionis Pharmaceuticals Inc(IONS) is 2024-05-03 Est..
Does Ionis Pharmaceuticals Inc(IONS) pay dividends? If so, how much?
Ionis Pharmaceuticals Inc(IONS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1